Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma - Drug Trials For Money

Conditions: Uveal Melanoma; Metastatic
Interventions: Drug: 4.7 microCi 225Ac-MTI-201; Drug: 9.5 microCi of 225Ac-MTI-201; Drug: 19 microCi of 225Ac-MTI-201; Drug: 38 microCi of 225Ac-MTI-201; Drug: 76 microCi of 225Ac-MTI-201; Drug: 152 microCi of 225Ac-MTI-201; Drug: 254 microCi of 225Ac-MTI-201; Drug: 424 microCi of 225Ac-MTI-201; Drug: 564 microCi of 225Ac-MTI-201; Drug: 750 microCi of 225Ac-MTI-201; Drug: 998 microCi of 225Ac-MTI-201; Drug: 1327 microCi of 225Ac-MTI-201
Sponsors: Modulation Therapeutics, Inc.; H. Lee Moffitt Cancer Center and Research Institute
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.